Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,433
  • Shares Outstanding, K 13,402
  • Annual Sales, $ 27,460 K
  • Annual Income, $ -17,810 K
  • 60-Month Beta 0.83
  • Price/Sales 2.14
  • Price/Cash Flow N/A
  • Price/Book 2.48
Trade BIOC with:

Options Overview

Details
  • Implied Volatility 155.82%
  • Historical Volatility 64.78%
  • IV Percentile 26%
  • IV Rank 6.69%
  • IV High 689.37% on 03/31/21
  • IV Low 117.57% on 01/13/21
  • Put/Call Vol Ratio 1.32
  • Today's Volume 218
  • Volume Avg (30-Day) 402
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 8,827
  • Open Int (30-Day) 5,708

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +124,975.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.23 +3.07%
on 04/12/21
6.40 -31.87%
on 03/30/21
-1.53 (-25.98%)
since 03/16/21
3-Month
4.23 +3.07%
on 04/12/21
8.38 -47.97%
on 02/16/21
-1.00 (-18.66%)
since 01/15/21
52-Week
3.46 +26.01%
on 09/11/20
13.00 -66.46%
on 08/06/20
+0.16 (+3.83%)
since 04/16/20

Most Recent Stories

More News
Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has...

BIOC : 4.36 (-0.68%)
Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

--Webinar begins tomorrow, April 8, at 12:00 p.m. Eastern Time

BIOC : 4.36 (-0.68%)
Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the use of the Company's proprietary...

BIOC : 4.36 (-0.68%)
Thinking about buying stock in Biocept, AbCellera Biologics, Novan, Seelos Therapeutics, or SRAX?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, ABCL, NOVN, SEEL, and SRAX.

ABCL : 29.82 (+2.83%)
NOVN : 1.1000 (-7.56%)
SEEL : 5.26 (-0.38%)
BIOC : 4.36 (-0.68%)
SRAX : 4.19 (-4.34%)
Biocept Reports 2020 Fourth Quarter and Full Year Financial Results

--Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system

BIOC : 4.36 (-0.68%)
Biocept to Report 2020 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 29, 2021

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 months ended December 31, 2020...

BIOC : 4.36 (-0.68%)
Biocept to Participate in Three Virtual Investment Conferences in March

--Provides update on COVID-19 testing with more than 300,000 samples received

BIOC : 4.36 (-0.68%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 38,250 shares...

BIOC : 4.36 (-0.68%)
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Aegea Biotechnologies, Inc., an innovative life science company with an extensive portfolio of issued patents in next-generation nucleic acid technologies, and Biocept, Inc. (Nasdaq: BIOC), a leading provider...

BIOC : 4.36 (-0.68%)
Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept's Target Selector(TM) Assay Kit for Non-Small Cell Lung Cancer Patients

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will collaborate with Protean BioDiagnostics Inc. to research the ability of Biocept's Target Selector(TM)...

BIOC : 4.36 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

3rd Resistance Point 4.59
2nd Resistance Point 4.50
1st Resistance Point 4.43
Last Price 4.36
1st Support Level 4.27
2nd Support Level 4.18
3rd Support Level 4.11

See More

52-Week High 13.00
Fibonacci 61.8% 9.36
Fibonacci 50% 8.23
Fibonacci 38.2% 7.10
Last Price 4.36
52-Week Low 3.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar